BMO Capital Markets launches coverage on Alnylam, BioMarin and Ionis with upbeat ratings

BMO Capital Markets initiated research coverage on three biotech firms on August 19, 2026. The firm assigned an "outperform" rating and a $318 price objective to Alnylam Pharmaceuticals, an "outperform" rating and a $98 target to BioMarin Pharmaceutical, and a "market perform" rating with a $60 target to Ionis Pharmaceuticals. These new ratings signal BMO's positive outlook on the RNA‑based therapeutics sector.

On August 19, 2026, BMO Capital Markets released a trio of analyst notes covering three RNA‑focused biotechnology companies. The firm issued an "outperform" rating and a $318 price objective for Alnylam Pharmaceuticals (ALNY) , an "outperform" rating with a $98 price target for BioMarin Pharmaceutical (BMRN) , and a "market perform" rating alongside a $60 target for Ionis Pharmaceuticals (IONS) .

These initiations come as the biotech sector continues to attract investor interest in gene‑silencing and mRNA therapeutics. By assigning higher-than‑average price objectives to Alnylam and BioMarin, BMO signals confidence in their pipeline progress and potential market adoption, while the more neutral stance on Ionis reflects a balanced view of its growth prospects.

The coverage notes were all published simultaneously via MarketBeat's news feed, indicating a coordinated research effort by BMO's healthcare team. The "outperform" ratings suggest the analysts expect the stocks to exceed broader market returns, whereas the "market perform" rating for Ionis implies expected performance in line with the sector average.

Investors should monitor upcoming clinical trial data, regulatory approvals, and partnership announcements that could validate or challenge these price targets. BMO's ratings may also influence institutional sentiment, potentially affecting trading volumes and valuation multiples across the RNA‑therapeutics space.

Related Stocks

ALNY